首页> 外文期刊>Clinical and experimental hypertension: CEH >Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
【24h】

Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.

机译:阿米洛利和螺内酯对基线期和速尿之后的高血压患者肾小管功能和中心血压的影响:一项双盲,随机,安慰剂对照的交叉试验。

获取原文
获取原文并翻译 | 示例
       

摘要

This study demonstrates that the increased potassium content in the body seems to change both the blood pressure and renal tubular function. We wanted to test the hypotheses that amiloride and spironolactone induced potassium retention reduces ambulatory blood pressure (ABP) and central blood pressure (CBP) during baseline conditions and after furosemide and that the tubular transport via the epithelial sodium channels (ENaCs) and aquaporin-2 (AQP2) water channels was increased by furosemide in arterial hypertension. Each of three 28-day treatment periods (placebo, amiloride, and spironolactone) was completed by a 4-day period with standardized diet regarding calories and sodium and water intake. At the end of each period, we measured pulse wave velocity (PWV), central systolic blood pressure (CSBP), central diastolic blood pressure (CDBP), glomerular filtration rate (GFR), free water clearance (CH2O), fractional excretion of sodium (FENa) and potassium (FEK), urinary excretion of AQP2 (u-AQP2), urinary excretion of γ-fraction of the ENaC (u-ENaCγ), and plasma concentrations of renin (PRC), angiotensin II (p-Ang II), and aldosterone (p-Aldo) at baseline conditions and after furosemide bolus. Ambulatory blood pressure and CBP were significantly lowered by amiloride and spironolactone. During 24-hour urine collection and at baseline, GFR, CH2O, FENa, FEK, u-AQP2 and u-ENaCγ were the same. After furosemide, CH2O, FENa, FEK, u-AQP2, u-ENaCγ, PRC, p-Ang II, p-Aldo, PWV and CDBP increased after all treatments. However, during amiloride treatment, FEK increased to a larger extent than after spironolactone and during placebo after furosemide, and CSBP was not significantly reduced. The increases in water and sodium absorption via AQP2 and ENaC after furosemide most likely are compensatory phenomena to antagonize water and sodium depletion. Amiloride is less effective than spironolactone to reduce renal potassium excretion.
机译:这项研究表明,体内钾含量的增加似乎会改变血压和肾小管的功能。我们想检验以下假设:阿米洛利和螺内酯引起的钾retention留会降低基线状态下和速尿后的门诊血压(ABP)和中心血压(CBP),以及通过上皮钠通道(ENaCs)和aquaporin-2进行的肾小管转运速尿在动脉高血压中增加了(AQP2)水通道。三个为期28天的治疗期(安慰剂,阿米洛利和螺内酯)中的每个治疗期均在4天的时间内完成,并采用有关卡路里,钠和水摄入量的标准化饮食。在每个周期的末尾,我们测量脉搏波速度(PWV),收缩压中心血压(CSBP),舒张压中心血压(CDBP),肾小球滤过率(GFR),游离水清除率(CH2O),钠的排泄量(FENa)和钾(FEK),AQP2(u-AQP2)的尿排泄,ENaC(u-ENaCγ)的γ分数的尿排泄以及肾素(PRC),血管紧张素II(p-Ang II)的血浆浓度)和醛固酮(p-Aldo)在基线条件下和速尿推注后。阿米洛利和螺内酯可显着降低动态血压和CBP。在24小时尿液收集期间和基线时,GFR,CH2O,FENa,FEK,u-AQP2和u-ENaCγ相同。速尿后,所有处理后CH2O,FENa,FEK,u-AQP2,u-ENaCγ,PRC,p-Ang II,p-Aldo,PWV和CDBP均升高。但是,在阿米洛利治疗期间,FEK的增加幅度大于螺内酯治疗后和速尿后的安慰剂治疗期间,CSBP并未显着降低。速尿后通过AQP2和ENaC吸收水和钠的增加很可能是拮抗水和钠消耗的补偿性现象。阿米洛利在减少肾脏钾排泄方面不如螺内酯有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号